Epithalon vs GDF-11 (Growth Differentiation Factor 11)
A neutral, side-by-side comparison of two anti-aging & longevity peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Epithalon
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from Epithalamin, a polypeptide extract of the pineal gland. It has been studied since the 1980s by Russian researchers, primarily Vladimir Khavinson, for its ability to activate telomerase and extend telomere length — one of the few compounds with direct evidence of telomere elongation in human cells.
Full profileGDF-11 (Growth Differentiation Factor 11)
TGF-β superfamily member proposed as a 'young blood factor' — circulating GDF-11 declines with age, and young plasma transfusion in parabiosis experiments reversed aging phenotypes in mice. A high-profile but contested research area: some studies show rejuvenating effects in heart, muscle, and brain; others using purified recombinant GDF-11 show cardiac hypertrophy and muscle wasting at pharmacologic doses.
Full profile| Epithalon | GDF-11 (Growth Differentiation Factor 11) | |
|---|---|---|
| Category | Anti-Aging & Longevity | Anti-Aging & Longevity |
| Also known as | Epitalon, Epithalone, Tetrapeptide Ala-Glu-Asp-Gly | GDF11, Bone Morphogenetic Protein 11, BMP-11, young blood factor |
| Evidence | Research-stage | Research-stage |
| Dosing range | 5mg–20mg mg, daily for 10–20 day cycles, 1–2x per year | 0.1mg/kg–1mg/kg mg/kg, every 3–7 days (SC); research protocols vary widely |
| Administration | Subcutaneous injection, Intravenous (clinical studies), Intranasal | Subcutaneous injection, Intravenous (research) |
| Key side effects | Generally very well-tolerated, Injection site discomfort, Vivid dreams (commonly reported), Improved sleep depth (often reported as benefit) | Cardiac hypertrophy (at pharmacologic doses — the key safety concern), Muscle wasting and weight loss, Reproductive effects (GDF-11 inhibits spermatogenesis and folliculogenesis), Cachexia-like syndrome at high doses |
| Cited sources | 2 references | 2 references |
Key differences
- Administration: Epithalon — Subcutaneous injection, Intravenous (clinical studies), Intranasal; GDF-11 (Growth Differentiation Factor 11) — Subcutaneous injection, Intravenous (research).
- Dosing units differ: Epithalon is dosed in mg, GDF-11 (Growth Differentiation Factor 11) in mg/kg — they operate at different scales.
- Frequency: Epithalon is typically daily for 10–20 day cycles, 1–2x per year; GDF-11 (Growth Differentiation Factor 11) is every 3–7 days (SC); research protocols vary widely.
How each works
Epithalon
Epithalon activates telomerase (hTERT), the enzyme responsible for maintaining telomere length. In vitro and animal studies show telomere elongation, extended cell lifespan, and reduced DNA oxidation. Russian clinical studies in aging populations report improved melatonin rhythms, immune function, and reduced cancer incidence over multi-year follow-up.
GDF-11 (Growth Differentiation Factor 11)
The 2013–2014 parabiosis studies from Amy Wagers' lab at Harvard proposed GDF-11 as the primary rejuvenating factor in young blood. However, subsequent work by Lee and others showed that purified recombinant GDF-11 at pharmacologic doses caused cardiac hypertrophy, muscle atrophy, and weight loss — opposite of the proposed rejuvenating effects. The field now views GDF-11 as highly dose-sensitive with a narrow therapeutic window, if one exists at all.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.